Uncategorized
Patients enrolled in phase 2b trial of adenoviral conjunctivitis candidate
NovaBay Pharmaceuticals has enrolled the first patients in Brazil as part of its phase 2b trial of an anti-infective compound as a treatment for adenoviral conjunctivitis, according to a company news release.The multicenter, randomized clinical study of Auriclosene (NVC-422) ophthalmic solution is designed to determine the compound’s efficacy in clearing the red eye, blurred vision and lingering effects left by an adenoviral infection.